Arca
Skip to content
Tools
Tools

Peritoneal cancer

Drug research and approvals for peritoneal cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 215 studies of peritoneal cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 21 drug trials for it since 2013, FDA has 12 approved and 4 open orphan designations naming it, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 215
  • Trials authorized in Canada: 21
  • FDA orphan approvals: 12
  • EU medicines: 4

Recruiting now

Newest posted first, of 215 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 3

Phase 3 12 of 20

Phase 2 12 of 74

Phase 1 or earlier 12 of 37

How its trials ended

385 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 101 whose ending is known, 30% met their primary endpoint, 12% missed it and 58% stopped early.

  • Completed, result not reported14137%
  • Ongoing10327%
  • Status unknown4010%
  • Stopped: other or unclear328%
  • Met its primary endpoint308%
  • Stopped: enrollment or feasibility144%
  • Missed its primary endpoint123%
  • Stopped: lack of efficacy82%
  • Stopped: funding31%
  • Stopped: sponsor or business decision21%

Trials authorized in Canada

The 10 newest of 21; search them all in Canada trials
Aug 26, 2026A randomised, open-label, phase III study of torvutatug samrotecan with or without bevacizumab versus standard of care as second- or third-line maintenance…AZD5335 / Avastin / VegzelmaAstraZeneca PharmaceuticalsPending
Aug 20, 2026A randomised, open-label, phase III study of torvutatug samrotecan in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance…Torvutatug samrotecan (AZD5335) / Avastin (bevacizumab) / Vegzelma (bevacizumab)AstraZeneca PharmaceuticalsPending
Dec 23, 2025A phase 1b/2 open-label, multicenter study to evaluate the safety and efficacy of raludotatug deruxtecan with or without other anticancer investigational…MK-5909 (raludotatug deruxtecan (r-dxd)) / Keytruda / Bevacizumab / Paclitaxel…Merck & Co. (MSD)Ongoing
Jun 12, 2024A phase 1, first-in-human, open-label, dose-escalation and expansion study of IMGN151 (anti-fr antibody-drug conjugate) in adult patients with recurrent…IMGN151AbbVieOngoing
Jan 18, 2023A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced, platinum-resistant high-grade epithelial…Relacorilant (CORT125134) / PaclitaxelCorcept TherapeuticsOngoing
Nov 9, 2022Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy…Mirvetuximab soravtansineAbbVieOngoing
Sep 29, 2022Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate…Mirvetuximab soravtansine (IMGN853)AbbVieOngoing
Feb 11, 2022Piccolo: a phase 2, single arm study of mirvetuximab soravtansine in recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or…Mirvetuximab soravtansine (IMGN853)AbbVieClosed
Oct 18, 2021A phase 3, multicenter, open-label, randomized study of nemvaleukin alfa in combination with pembrolizumab versus investigator's choice chemotherapy in…Alks 4230 / KeytrudaMural OncologyOngoing
Feb 19, 2020Mirasol: a randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial…Mirvetuximab soravtansine (IMGN853)AbbVieOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 16
Nov 14, 2022ElahereTreatment of adult patients with folate receptor-alpha (FR?) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary…ImmunoGen, Inc.Approved
May 8, 2020LynparzaLynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian,…AstraZeneca Pharmaceuticals LPApproved
May 8, 2020LynparzaLynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian,…AstraZeneca Pharmaceuticals LPApproved
May 8, 2020LynparzaLynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian,…AstraZeneca Pharmaceuticals LPApproved
Apr 29, 2020ZejulaZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal…GlaxoSmithKline, LLC.Approved
Oct 23, 2019ZejulaZEJULA? is indicated for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been…GlaxoSmithKline, LLC.Approved
Dec 19, 2018LynparzaLynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic…AstraZeneca Pharmaceuticals LPApproved
Apr 6, 2018RubracaFor the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in…pharma&Approved
Aug 17, 2017LynparzaMaintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a…AstraZeneca Pharmaceuticals LPApproved
Aug 17, 2017LynparzaMaintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a…AstraZeneca Pharmaceuticals LPApproved
Aug 17, 2017LynparzaMaintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a…AstraZeneca Pharmaceuticals LPApproved
Mar 27, 2017ZejulaIndicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who…GlaxoSmithKline, LLC.Approved
Mar 2, 2026RezatapoptTreatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancerPMV Pharmaceuticals, Inc.Designated
Aug 27, 2024N-[5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluor…Treatment of AT-rich interactive domain-containing protein 1a (ARID1a)-deficient ovarian cancer, fallopian tube cancer, and primary…Nuvectis Pharma, Inc.Designated
Feb 15, 2024GleolanDiagnostic for the management of ovarian, fallopian tube, and primary peritoneal cancerNX Development Corp.Designated

Medicines authorised in the EU

Newest first
Nov 14, 2024ElahereMirvetuximab soravtansine · orphanAbbVie Deutschland GmbH & Co. KGEMA ↗
Jul 26, 2024AvziviBevacizumab · biosimilarFGK Representative Service GmbHEMA ↗
May 23, 2018RubracaRucaparibpharmaand GmbHEMA ↗
Nov 16, 2017ZejulaNiraparib · orphanGlaxoSmithKline Trading Services LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.